About this trial
Pulmonary vein isolation is the main treatment of paroxysmal and persistent atrial fibrillation.
The aim of our study is to prospectively compare the efficacy and safety of the 3 options of radiofrequency delivery with QDOT Micro™, with systematic use of catheter stabilization tools and tighter lesions
Eligibility criteria
Qualifiers
Patient aged 18 or over
First atrial fibrillation ablation
Paroxysmal atrial fibillation defined as atrial fibrillation lasting less than 48 hours
Early atrial fibrillation defined as atrial fibrillation lastiing between 7 days and 3 months
Disqualifiers
History of atrial fibrillation ablation (surgery or catheter)
Documented left atrial thrombus
Left atrial (LA) diameter > 60mm / LA area > 35cm2 / Left atrial volulme index (LAVI) > 45ml/m2
N/STEMI replacement or angioplasty or valve within 3 months prior to registration
Trial design
Treatments tested in this trial
- Q-MODE : radiofrequency ablation up to 50W
- Q-MODE+ : radiofrequency up to 90W
- Hybride Q-MODE/Q-MODE+: radiofrequency ablation up to 50W in the anterior part, and 90W in the posterior part